EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative study of efficacy and safety: Biosimilar rituximab versus originator rituximab in the treatment of pemphigus

Sang Heon Shin, Jae Yeon Kim iD, Soo-Chan Kim, Jong Hoon Kim iD

The Journal of Dermatology · 2024

DOI: 10.1111/1346-8138.17329 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Sang Heon Shin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Rituximab, Pemphigus, Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rituximab is a monoclonal antibody that targets CD20 antigen in B cells. For pemphigus, rituximab has been highly effective in steroid‐sparing therapy for moderate to severe cases. Originator rituximab has demonstrated favorable treatment effects in patients with pemphigus, but its high cost remains a challenge. Biosimilar rituximab is expected to offer a potential solution. However, it is required for the comparative study of efficacy and safety between biosimilar and originator because all biosimilars may not be identical to the originator. In this study, we compared the treatment effects and safety of biosimilar (Truxima) and originator (MabThera) rituximab in patients with pemphigus. A final cohort of 52 patients in the MabThera group and 72 patients in the Truxima group was enrolled. Except for the intravenous immunoglobulin administration rate, there were no differences in baseline characteristics between the two groups, and for the purpose of comparing efficacy, investigations into time to complete remission, total steroid intake to complete remission, and total steroid intake for 6 months following rituximab treatment revealed no significant differences between the two groups. Truxima can be considered a relatively affordable alternative treatment option for pemphigus, offering cost‐effectiveness to patients who are indicated for the treatment with MabThera.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabPemphigusBiosimilar PharmaceuticalsHumansMaleFemaleMiddle AgedAdultTreatment OutcomeAgedImmunologic FactorsRemission InductionRetrospective Studies

Stichwörter der Autor:innen

biosimilaroriginatorpemphigus foliaceuspemphigus vulgarisrituximab

Substanzen

RituximabBiosimilar PharmaceuticalsImmunologic Factors

Autor:innen und Institutionen

  • Department of Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Dermatology, Gangnam Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Dermatology, Yongin Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Gyeonggi-do, Korea.

ORCID-Profile: Jae Yeon Kim, Jong Hoon Kim

Förderung

  • Korea Health Industry Development Institute

Zitieren

APA

Shin, S. H., Kim, J. Y., Kim, S. C., & Kim, J. H. (2024). Comparative study of efficacy and safety: Biosimilar rituximab versus originator rituximab in the treatment of pemphigus. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17329

Vancouver

Shin SH, Kim JY, Kim SC, Kim JH. Comparative study of efficacy and safety: Biosimilar rituximab versus originator rituximab in the treatment of pemphigus. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17329

BibTeX
@article{Shin2024,
  author = {Shin, Sang Heon and Kim, Jae Yeon and Kim, Soo-Chan and Kim, Jong Hoon},
  title = {Comparative study of efficacy and safety: Biosimilar rituximab versus originator rituximab in the treatment of pemphigus},
  journal = {The Journal of Dermatology},
  year = {2024},
  doi = {10.1111/1346-8138.17329}
}
Kostenlos starten →